StockDuty ← Dashboard Nov 17, 2026 07:56 AM ET
SignalMacro

Electra Therapeutics: A Broken IPO Leaves The SIRP Platform Nearly Free

High-priority alert based on source significance and keyword relevance.

What happened: Electra Therapeutics is described as offering cash-backed asymmetry after a broken IPO, with its pipeline valued at roughly $150 million enterprise value. Key numbers: Pipeline valued at roughly $150 million enterprise value. Ipsoprubart delivered 100% eight-week survival in 12 frontline malignancy-associated sHLH patients. Cash runway into 2029. Why it matters: The article frames regulatory acceptance of SURPASS's external comparator as the central risk, while noting future financing, potential lock-up selling, and competing regimens also warrant monitoring.
Electra Therapeutics is described as offering cash-backed asymmetry after a broken IPO, with its pipeline valued at roughly $150 million enterprise value.
The article frames regulatory acceptance of SURPASS's external comparator as the central risk, while noting future financing, potential lock-up selling, and competing regimens also warrant monitoring.
Sources